Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand name Poviztra in India. This collaboration aims to expand ...

Poviztra to be sold as 2.4 mg injectable; Emcure becomes first Indian firm with exclusive semaglutide distribution rights ...

Emcure becomes first Indian company to commercialise semaglutide 2.4 mg, the second brand of Wegovy®, in India.

The Indian subsidiary of Danish pharma major Novo Nordisk has partnered with Pune-based Emcure Pharma to expand the reach of ...

Danish drugmaker Novo Nordisk announced a partnership with Emcure Pharma on Monday to launch its Poviztra, semaglutide injection 2.4 mg, in India. Poviztra is the second brand of its weight loss drug ...

This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths ...

Novo Nordisk and Emcure Pharma team up to bring Poviztra, a new weight loss injection, to India. Learn more about this latest ...

Secondary analyses of the ESSENCE trial were presented at the American Association for the Study of Liver Diseases (AASLD), ...

Novo Nordisk partners with Emcure Pharma to launch Poviztra (semaglutide) for weight loss in India. Expanding access to ...

Poviztra (semaglutide injection 2.4 mg) is the second brand of Wegovy, Novo Nordisk’s blockbuster obesity medication, which ...

Novo Nordisk India has joined forces with Emcure Pharmaceuticals to commercialize Poviztra, a weight-loss drug, in an effort ...

Novo Nordisk India and Emcure Pharma today announced a strategic partnership to launch Poviztra, semaglutide injection 2.4 mg, in India. The collaboration will strengthen the distribution and ...